Last reviewed · How we verify
NCT05308784
A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients
trial testing Cellworks Singula and Ventura reports in Pan-cancer in 730 participants. Status unknown.
31 December 2025
Quick facts
| Lead sponsor | Avera McKennan Hospital & University Health Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 730 |
| Start date | 1 January 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cellworks Singula and Ventura reports
Conditions studied
- Pan-cancer — all drugs for Pan-cancer →
Sponsor
Avera McKennan Hospital & University Health Center
Who can join
Eligibility, any sex, with Pan-cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the benefit of Cellworks Singula™ and Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications. Cellworks reports aim to provide NGS-based therapy recommendations to aid the decision-making of patients, physicians, and molecular tumor boards.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Expanding the immunotherapy universe in extensive-stage small cell lung cancer: from chemoimmunotherapy backbone to next-wave combinations.
Chi X, Dong Y, Zhu L, Su D, et al · · 2025 · PMID 41415276 · DOI 10.3389/fimmu.2025.1693401
Verify or expand the search:
- PubMed search for NCT05308784
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Avera McKennan Hospital & University Health Center trials
Trials by the same sponsor.
- NCT05142033 — Avera Cancer Sequencing and Analytics Protocol (ASAP) · recruiting
- NCT03494621 — Infant Care Practices Study · NA · completed
- NCT03345277 — Continuous Temperature Measurement for Syndromic Surveillance · withdrawn
- NCT03154281 — Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast · Phase 1 · completed
- NCT03154294 — Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05308784 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Avera McKennan Hospital & University Health Center
- Last refreshed: 19 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05308784.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing